5 Key Takeaways

• 1

  The CREST study evaluated real-world safety outcomes in 575 eyes treated with biointerventional uveoscleral outflow enhancement.

• 2

  At 2 years, the reported adverse event rate was 15%.

• 3

  At 2 years, 65% of eyes that otherwise would have been considered for bleb-forming surgery remained free of those procedures.

• 4

  Mean intraocular pressure was approximately 30% lower than baseline at 2 years.

• 5

  At 2 years, patients were using 1 fewer medication than at baseline.